Glycation burden and glycemic variability: Key drivers of chronic venous insufficiency severity and adverse outcomes
Open Access
- 21 July 2025
- journal article
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 34 (2) , 155-63
Abstract
Aim: Advanced glycation end-products (AGEs) have been implicated in vascular pathology, but their role in chronic venous insufficiency (CVI) remains underexplored. This study investigated the association between glycated hemoglobin (HbA1c), a surrogate marker of glycation burden, and CVI severity and outcomes.Material and Methods: This single-center retrospective cohort study included 612 patients with CVI. Patients were stratified by glycation burden: high (high glycation burden (HGB); HbA1c ≥6.5%, n=247) and low (low glycation burden (LGB); HbA1c <6.5%, n=365). CVI severity was assessed using Clinical, Etiological, Anatomical, and Pathophysiological (CEAP) classification and Venous Clinical Severity Score (VCSS). Major adverse venous events (MAVEs) were tracked over 36 months.Results: HGB patients showed higher rates of advanced CVI (CEAP C4-C6: 41.7% vs. 26.0%, p<0.001) and higher VCSS scores (median 9 vs. 7, p<0.001). HbA1c variability (SD) strongly correlated with VCSS (ρ=0.38, p<0.001). In multivariable analysis, HbA1c ≥6.5% (OR 1.52, 95% CI 1.02-2.30), HbA1c SD (OR 2.10, 95% CI 1.45-3.06), and HOMA-IR (OR 1.19, 95% CI 1.07-1.33) independently predicted severe CVI. MAVEs were more frequent in HGB patients (14.2% vs. 8.5%, p=0.021).Conclusion: Glycation burden and glycemic variability are independently associated with CVI severity and adverse outcomes. These findings suggest that metabolic dysfunction contributes to venous pathology and may represent potential therapeutic targets.Keywords
This publication has 25 references indexed in Scilit:
- Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progressionGlycoconjugate Journal, 2021
- The aging venous system: from varicosities to vascular cognitive impairmentGeroScience, 2021
- Glycaemic variability in diabetes: clinical and therapeutic implicationsThe Lancet Diabetes & Endocrinology, 2019
- Serum albumin and health in older people: Review and meta analysisMaturitas, 2015
- Role of insulin resistance in endothelial dysfunctionReviews in Endocrine and Metabolic Disorders, 2013
- The effects of aging on the intimal region of the human saphenous vein: insights from multimodal microscopy and quantitative image analysisHistochemistry and Cell Biology, 2012
- Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetesMedical Hypotheses, 2008
- Duplex Ultrasound Investigation of the Veins in Chronic Venous Disease of the Lower Limbs—UIP Consensus Document. Part II. AnatomyEuropean Journal of Vascular and Endovascular Surgery, 2006
- Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetesCardiovascular Research, 2004
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001